PerkinElmer’s Oxford Immunotec receives U.S. FDA approval for T-cell select to automate clinically superior tuberculosis detection

PerkinElmer’s (NYSE: PKI) Oxford Immunotec today announced the U.S. Food and Drug Administration (FDA) has approved the use of the T-Cell Select™ reagent kit for the automation of its T-SPOT®.TB test workflow for in vitro diagnostic (IVD) use by certified laboratories.

The T-Cell Select reagent kit allows for a more automated workflow, designed to reduce hands-on time for lab personnel and lower overall costs. The increased use of automation also improves blood sample logistics, as it allows for a standard blood collection tube which can be stored at room temperature for up to 54 hours with no complex phlebotomy practices. The extended blood sample stability enables easy centralization of sample processing, which expands access to the T-SPOT.TB test and gives laboratories more flexibility with the potential for sample batching.

T-Cell Select is a peripheral blood mononuclear cell (PBMC) isolation reagent that uses positive selection of PBMCs with magnetic bead-based cell separation to automate and simplify the preparation of cells for the T-SPOT.TB test, a globally regulated ELISPOT IGRA for detecting latent TB infection. The T-SPOT.TB test with the T-Cell Select reagent kit is the only automated IGRA TB test without regulatory (label) warnings for immunocompromised patients, who often have lower levels of T cells available to evaluate.

Automation closes the gap between ELISPOT and ELISA laboratory workflows, enabling more laboratories to offer the clinically superior T-SPOT.TB test to more physicians,”

Phill Keefe, chief executive officer of PerkinElmer’s Oxford Immunotec division.

“This results in the highest quality of care for the most vulnerable patients across the United States.”

The T-Cell Select reagent kit is available throughout Europe where CE marking is accepted, South Korea by the Ministry of Food and Drug Safety, China by the National Medical Products Administration (NMPA) and is quickly becoming available in more markets around the world.

About PerkinElmer

PerkinElmer is a leading, global provider of end-to-end solutions that help scientists, researchers and clinicians better diagnose disease, discover new and more personalized drugs, monitor the safety and quality of our food, and drive environmental and applied analysis excellence. With an 85-year legacy of advancing science and a mission of innovating for a healthier world, our dedicated team of more than 16,000 collaborates closely with commercial, government, academic and healthcare customers to deliver reagents, assays, instruments, automation, informatics and strategic services that accelerate workflows, deliver actionable insights and support improved decision making. We are also deeply committed to good corporate citizenship through our dynamic ESG and sustainability programs. The Company reported revenues of approximately $5 billion in 2021, serves customers in 190 countries, and is a component of the S&P 500 index. Additional information is available at www.perkinelmer.com. Follow PerkinElmer on LinkedInTwitterFacebookInstagram, and YouTube.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Oxford Immunotec. (2022, October 06). PerkinElmer’s Oxford Immunotec receives U.S. FDA approval for T-cell select to automate clinically superior tuberculosis detection. News-Medical. Retrieved on December 03, 2022 from https://www.news-medical.net/news/20221006/PerkinElmere28099s-Oxford-Immunotec-receives-US-FDA-approval-for-T-cell-select-to-automate-clinically-superior-tuberculosis-detection.aspx.

  • MLA

    Oxford Immunotec. "PerkinElmer’s Oxford Immunotec receives U.S. FDA approval for T-cell select to automate clinically superior tuberculosis detection". News-Medical. 03 December 2022. <https://www.news-medical.net/news/20221006/PerkinElmere28099s-Oxford-Immunotec-receives-US-FDA-approval-for-T-cell-select-to-automate-clinically-superior-tuberculosis-detection.aspx>.

  • Chicago

    Oxford Immunotec. "PerkinElmer’s Oxford Immunotec receives U.S. FDA approval for T-cell select to automate clinically superior tuberculosis detection". News-Medical. https://www.news-medical.net/news/20221006/PerkinElmere28099s-Oxford-Immunotec-receives-US-FDA-approval-for-T-cell-select-to-automate-clinically-superior-tuberculosis-detection.aspx. (accessed December 03, 2022).

  • Harvard

    Oxford Immunotec. 2022. PerkinElmer’s Oxford Immunotec receives U.S. FDA approval for T-cell select to automate clinically superior tuberculosis detection. News-Medical, viewed 03 December 2022, https://www.news-medical.net/news/20221006/PerkinElmere28099s-Oxford-Immunotec-receives-US-FDA-approval-for-T-cell-select-to-automate-clinically-superior-tuberculosis-detection.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post